COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00541385
Recruitment Status : Completed
First Posted : October 10, 2007
Last Update Posted : May 4, 2020
Shin Poong Pharmaceuticals
Information provided by (Responsible Party):
Medicines for Malaria Venture

Brief Summary:
  • The primary objective of this clinical study is to demonstrate the efficacy of the fixed combination of pyronaridine artesunate granule formulation (60:20 mg; paediatric PYRAMAX®) by showing a PCR-corrected adequate clinical and parasitological cure rate of more than 90%.
  • Treatment success or failures will be classified according to WHO Guidelines 2005

Condition or disease Intervention/treatment Phase
Malaria Drug: pyronaridine artesunate Drug: arthemeter lumefantrine Phase 3

Detailed Description:

The need for safe and efficacious anti-malarial treatments for infants and children is huge given that they are the major group affected by acute uncomplicated malaria. There are relatively few paediatric formulations of artemisinin combination therapies. In addition to the tablet formulation of pyronaridine artesunate (PA) (PYRAMAX), Shin Poong Pharm Co is developing a paediatric dosing form presented as a granule formulation, packed in appropriate aluminium sachets each containing 60mg pyronaridine tetraphosphate and 20mg artesunate.

This Phase III study is designed to demonstrate that the efficacy of PA granule formulation, as assessed in terms of PCR-corrected APCR, is above 90% and subsequently to compare (non-inferiority) the efficacy and safety of PA granule formulation to Coartem® crushed tablets in infants and children.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 535 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase III Comparative, Open-labelled, Randomised, Clinical Study to Assess a Fixed Dose of Oral Pyronaridine Artesunate Granule Formulation vs. Coartem® Crushed Tablets in Infants With Acute Uncomplicated Plasmodium Falciparum Malaria
Study Start Date : October 2007
Actual Primary Completion Date : September 2008
Actual Study Completion Date : November 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malaria

Arm Intervention/treatment
Experimental: 1
60mg pyronaridine and 20mg artesunate fixed dose combination granule formulation for 3 consecutive days
Drug: pyronaridine artesunate
The strength of the granule formulation is 60:20 mg pyronaridine artesunate per sachet. Depending on their body weight, patients will receive between 1 to 3 pyronaridine artesunate sachets per day, for 3 consecutive days The actual dose-range covered by this regimen is 7.0:2.3 mg/kg to 13.3:4.4 mg/kg pyronaridine artesunate, which has shown to be effective and safe in the phase II studies conducted in children and adults.
Other Name: Pyramax

Active Comparator: 2
120mg lumefantrine and 20mg Artemether fixed dose combination crushed tablets, twice a day for 3 days
Drug: arthemeter lumefantrine

Artemether 20 mg and lumefantrine 120 mg fixed dose combination, 6 dose regimen 120 mg artemether and 720 mg lumefantrine total (Novartis).

The posology is twice daily for 3 consecutive days 1 tablet for patients weighing ≥5 kg to <15 kg, 2 tablets for patients weighing ≥15 to <25 kg.

Other Name: Coartem

Primary Outcome Measures :
  1. PCR corrected ACPR on Day 28 [ Time Frame: Day 28 ]

Secondary Outcome Measures :
  1. PCR-corrected ACPR on Day 14 [ Time Frame: Day 14 ]
  2. Incidence and severity of adverse events and of cllinically significant laboratory results, ECG, vital signs or physical examination abnormalities [ Time Frame: Day 28 and Day 42 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female patients ≤12 years of age.
  2. Body weight ≥ 5 kg and < 25 kg with no clinical evidence of severe malnutrition (defined as a child whose weight-for-height is below -3 standard deviations or less than 70% of the median of the NCHS/WHO normalised reference values).
  3. Presence of acute uncomplicated P. falciparum mono-infection confirmed by:

    1. Fever, as defined by axillary temperature ≥ 37.5°C or oral/tympanic/rectal temperature ≥ 38°C, or documented history of fever in the previous 24 hours and,
    2. Positive microscopy of P. falciparum with parasite density between 1,000 and 200,000 asexual parasite count/µl of blood.
  4. Written informed consent, in accordance with local practice, provided by parent/guardian. If the parent/guardian is unable to write, witnessed consent is permitted according to local ethical considerations. Where possible, patient assent will be sought.
  5. Ability to swallow whole volume of liquid in which medication is suspended.
  6. Female patients of child-bearing potential must be neither pregnant (as demonstrated by a negative pregnancy test) nor lactating, and must be willing to take measures to not become pregnant during the study period.
  7. Ability and willingness to participate based on information given to parent or guardian and access to health facility. The patient is to comply with all scheduled follow up visits until D42.

Exclusion Criteria:

  1. Patients with signs and symptoms of severe/complicated malaria requiring parenteral treatment according to the World Health Organization Criteria 2000 [Attachment 3].
  2. Mixed Plasmodium infection.
  3. Severe vomiting, defined as more than three times in the 24 hours prior to inclusion in the study or inability to tolerate oral treatment, or severe diarrhoea defined as 3 or more watery stools per day.
  4. Known history or evidence of clinically significant disorders such as cardiovascular (including arrhythmia, QTc interval greater or equal to 450 milliseconds), respiratory (including active tuberculosis), history of jaundice, hepatic, renal, gastrointestinal, immunological (including active HIV-AIDS), neurological (including auditory), endocrine, infectious, malignancy, psychiatric, history of convulsions or other abnormality (including recent head trauma).
  5. Presence of significant anaemia, as defined by Hb < 8 g/dL.
  6. Presence of febrile conditions caused by diseases other than malaria.
  7. Known history of hypersensitivity, allergic or adverse reactions to pyronaridine, lumefantrine or artesunate or other artemisinins.
  8. Patients with known disturbances of electrolytes balance, e.g., hypokalaemia or hypomagnesaemia.
  9. Use of any other antimalarial agent within 2 weeks prior to start of the study as evidenced by reported patient history.
  10. Pregnant or breast feeding.
  11. Patients taking any drug which is metabolised by the cytochrome enzyme CYP2D6 (flecainide, metoprol, imipramine, amitriptyline, clomipramine).
  12. Received an investigational drug within the past 4 weeks.
  13. Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody (HCV Ab).
  14. Known positive for HIV antibody.
  15. Liver function tests [ASAT/ALAT levels] more than 2.5 times upper limit of normal range.
  16. Known significant renal impairment as indicated by serum creatinine of more than 1.4 mg/dL.
  17. Previous participation in any clinical study with pyronaridine artesunate.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00541385

Layout table for location information
Burkina Faso
Centre National de Recherche et de Formation sur le Paludisme
Ouagadougou, Burkina Faso
Congo, The Democratic Republic of the
Ecole de Santé Publique, Faculté de Médecine, Université de Kinshasa
Kinshasa, Congo, The Democratic Republic of the
Côte D'Ivoire
Unité de Paludologie de l'Institut Pasteur d'Abidjan
Abidjan, Côte D'Ivoire
Medical Research Unit, Albert Schweitzer Hospital
Lambaréné, Gabon
Siaya District Hospital, Medical Superintendent's office
Siaya, Kenya
Malaria Research and Training Center, Faculté de Médecine, de Pharmacie et d'Ondonto-stomatologie
Bamako, Mali
Instituto Nacional de Saude, Ministero de Saude
Maputo, Mozambique
Puerto Princesa General Hospital
Puerto Princesa, Philippines
Sponsors and Collaborators
Medicines for Malaria Venture
Shin Poong Pharmaceuticals
Layout table for investigator information
Study Director: Claude Oeuvray, PhD Medicines for Malaria Venture
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Medicines for Malaria Venture Identifier: NCT00541385    
Other Study ID Numbers: SP-C-007-07
First Posted: October 10, 2007    Key Record Dates
Last Update Posted: May 4, 2020
Last Verified: April 2020
Keywords provided by Medicines for Malaria Venture:
Additional relevant MeSH terms:
Layout table for MeSH terms
Malaria, Falciparum
Protozoan Infections
Parasitic Diseases
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Antiplatyhelmintic Agents